Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effects of GIP and GLP-1 infusion on MR-proANP levels.

Published byRiitta Lahtinen Modified over 5 years ago

Similar presentations

Presentation on theme: "Effects of GIP and GLP-1 infusion on MR-proANP levels."— Presentation transcript:

1 Effects of GIP and GLP-1 infusion on MR-proANP levels.
Effects of GIP and GLP-1 infusion on MR-proANP levels. A: Infusion of placebo, GIP, GLP-1, or a combination of both incretin hormones in the cohort I (n = 12). B: Infusion of placebo or GIP in the cohort II (n = 8). Data are shown as mean ± SE. Statistical analysis was done by two-way repeated-measures ANOVA (A, by treatment; B, by time; AB, interaction of treatment and time). MR-proANP levels at different time points within single treatments were compared by one-way repeated-measures ANOVA. aP < 0.05 for placebo, bP < 0.05 for GIP infusion, cP < 0.05 for GLP-1 infusion, and dP < 0.05 for GIP + GLP-1 infusion vs. basal MR-proANP level. Natalia Rudovich et al. Dia Care 2015;38:e7-e8 ©2015 by American Diabetes Association

Download ppt "Effects of GIP and GLP-1 infusion on MR-proANP levels."

Similar presentations

Fig. 15.1 Summary of physiological function of the incretins GLP-1 and GIP on islet cells The Islets of Langerhans, Islam, Md. Shahidul (Ed.) ISBN: 978-90-481-3270-6,

Fig Summary of physiological function of the incretins GLP-1 and GIP on islet cells The Islets of Langerhans, Islam, Md. Shahidul (Ed.) ISBN: ,
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.

 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
Mean 24-Hour, Daytime, and Night Ambulatory Systolic BP, Diastolic BP, and PP Before (Week 0) and After (Week 12) NAG and Placebo Intake in 37 Hypertensive.

Mean 24-Hour, Daytime, and Night Ambulatory Systolic BP, Diastolic BP, and PP Before (Week 0) and After (Week 12) NAG and Placebo Intake in 37 Hypertensive.
Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.

Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.
Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.
Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.
(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).
Whole-body glucose kinetics in C and T2D-O during postabsorptive and clamp states. Whole-body glucose kinetics in C and T2D-O during postabsorptive and.

Whole-body glucose kinetics in C and T2D-O during postabsorptive and clamp states. Whole-body glucose kinetics in C and T2D-O during postabsorptive and.
Performance of chronic METH-treated rats in the gambling test under the double-reward condition. Performance of chronic METH-treated rats in the gambling.

Performance of chronic METH-treated rats in the gambling test under the double-reward condition. Performance of chronic METH-treated rats in the gambling.
Group differences (DKA vs

Group differences (DKA vs
A–F: Xenin-25 amplifies the insulin secretory response to GIP in humans with NGT and IGT but not T2DM. A–F: Xenin-25 amplifies the insulin secretory response.

A–F: Xenin-25 amplifies the insulin secretory response to GIP in humans with NGT and IGT but not T2DM. A–F: Xenin-25 amplifies the insulin secretory response.
A and B: Plasma levels of IR-GIP and xenin-25 during GGIs

A and B: Plasma levels of IR-GIP and xenin-25 during GGIs
Glucose, insulin, and AGE levels during an OGC before and after RT

Glucose, insulin, and AGE levels during an OGC before and after RT
Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.
Decreased GLP-1 receptor expression in islets after exposure to high glucose. Decreased GLP-1 receptor expression in islets after exposure to high glucose.

Decreased GLP-1 receptor expression in islets after exposure to high glucose. Decreased GLP-1 receptor expression in islets after exposure to high glucose.
Mean mesangial area (micron2) across normal controls (normal C), patients with type 2 diabetes and normoalbuminuria (normo), patients with type 2 diabetes.

Mean mesangial area (micron2) across normal controls (normal C), patients with type 2 diabetes and normoalbuminuria (normo), patients with type 2 diabetes.
Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.

Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.
Arterial plasma glucose level and peripheral GIR in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with vehicle.

Arterial plasma glucose level and peripheral GIR in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with vehicle.
Prevalence of high SAT or high VAT by BMI category in women (A) and men (B) and by waist circumference category in women (C) and men (D). Prevalence of.

Prevalence of high SAT or high VAT by BMI category in women (A) and men (B) and by waist circumference category in women (C) and men (D). Prevalence of.
Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes. Saxagliptin improves glycemic control in younger and older.

Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes. Saxagliptin improves glycemic control in younger and older.

Similar presentations

Ads by Google